Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers ; volume:7 ; number:1 ; day:21 ; month:8 ; year:2017 ; pages:1-15 ; date:12.2017
Scientific reports ; 7, Heft 1 (21.8.2017), 1-15, 12.2017
- Creator
-
Koch, Kathrin
Kalusche, Sarah
Torres, Jonathan L.
Stanfield, Robyn L.
Danquah, Welbeck
Khazanehdari, Kamal
Briesen, Hagen von
Geertsma, Eric R.
Wilson, Ian A.
Wernery, Ulrich
Koch-Nolte, Friedrich
Ward, Andrew B.
Dietrich, Ursula
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-017-08273-7
- URN
-
urn:nbn:de:101:1-2019102014540918995458
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Koch, Kathrin
- Kalusche, Sarah
- Torres, Jonathan L.
- Stanfield, Robyn L.
- Danquah, Welbeck
- Khazanehdari, Kamal
- Briesen, Hagen von
- Geertsma, Eric R.
- Wilson, Ian A.
- Wernery, Ulrich
- Koch-Nolte, Friedrich
- Ward, Andrew B.
- Dietrich, Ursula
- SpringerLink (Online service)
Other Objects (12)
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability
Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG
Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
![Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].
Lactobacilli expressing broadly neutralizing nanobodies against HIV-1 as potential vectors for HIV-1 prophylaxis?
P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape
HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure
Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability
Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG
Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].
Lactobacilli expressing broadly neutralizing nanobodies against HIV-1 as potential vectors for HIV-1 prophylaxis?
P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape
HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure
Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability
Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG
Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].
Lactobacilli expressing broadly neutralizing nanobodies against HIV-1 as potential vectors for HIV-1 prophylaxis?
P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape
HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure